Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)

NCT06285422 is registered in ClinicalTrials.gov with Sana Biotechnology as lead sponsor.

NCT NCT06285422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06285422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)
Lead sponsor
Sana Biotechnology
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 18, 2024
Completion date
March 31, 2029
Enrollment
6 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma, non hodgkin's lymphoma